95 results about "CARCINOMA BREAST" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention relates to a method for diagnosing a tumour disease in an isolated sample, comprising the amplification of methylated DNA sequences, to a kit for diagnosing a tumour disease, and to the use of the method and / or of the kit for the diagnosis and / or progress control of a malignant tumour disease, in particular of prostate, breast, ovarian or colorectal carcinomas. The invention furthermore relates to a computer program product comprising risk score analysis commands for diagnosing a tumour disease, and to a data processing device.

A method of treating cancer cells includes exposing the cancer cells to a ZrO2 / CaSiO3 / g-C3N4 nanocomposite material. The ZrO2 / CaSiO3 / g-C3N4 nanocomposite material comprises spherical metal oxide nanoparticles comprising a ZrO2 phase and a CaSiO3 phase dispersed on a matrix of g-C3N4 nanosheets, wherein the spherical metal oxide nanoparticles have an average particle diameter in a range from 3 to 18 nm, and wherein the ZrO2 / CaSiO3 / g-C3N4 nanocomposite material has a percent inhibition for human breast carcinoma (MCF-7) cells greater than or equal to 80% inhibition in an in-vitro cellular viability assay.

The invention discloses a culture medium and a culture method of a breast cancer organoid. The culture medium comprises an Advanced DMEM / F12 basal culture medium and an additive, the additive is prepared from penicillin streptomycin / amphotericin B, a B-27 additive, L-glutamine amide, HEPES (Hydroxyethyl PES), N-Acetylcysteine, nicotinamide, SB202190, A83-01, FGF10 (Fibroblast Growth Factor 10), EGF (Epidermal Growth Factor), human Hergulin beta-1, Y27632, WNT-3A, R-spondin 1, NOGGIN (Nitrogen Growth Factor IN), FGF7 (Fibroblast Growth Factor 7) and beta-estradiol. The culture method of the breast cancer organoid comprises the step of using the breast cancer organoid culture medium, and the method specifically comprises the steps of tissue sample taking, primary tissue construction, breast cancer organoid liquid changing and breast cancer organoid subculture. According to the prepared breast cancer organoid culture medium, tumor cells taken from breast cancer tumors grow fast, the cell speed is high, and follow-up medicine screening experiments can be facilitated; after the breast cancer organoid culture medium is used for culturing the breast cancer organoid, the cellular morphology and the protein expression condition of the organoid are identified through HE and immunohistochemistry, and it can be seen that the organoid can well reduce the pathological characteristics of the tissue.

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer such as, for example, a primary or secondary tumor within a subject's brain, breast, kidney, pancreas, lung, colon, prostate, lymphatic system, liver, ovary, or cervix. Additional examples of cancers for which the disclosed compounds and compositions can be useful include, but are not limited to, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanomas, gliomas, leukemia, lymphoma, chronic myeloproliferative disorders, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinomas, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention provides a medicinal compound comprising a synthetic flavonoid derivative according to formula (I), which has a group at the C-3 position: wherein at least two of R2-R6 are H, and the rest are independently selected from: H, OH, R1, OR1, NO2, NH2, NHR1, F, Cl, Br, I; wherein R1 is a free radical. The present invention also provides dimerization, trimerization and tetramerization compounds, wherein two or more quercetin units are connected to a central linker (skeleton) via position 3 and a spacer. The medicinal compound can be used to treat malignant tumors, in particular malignant epithelial tumors, such as colon cancer, melanoma and / or squamous cell carcinoma of the skin, lung cancer, breast cancer, basal cell carcinoma (basal cell tumor). #imgabs0#

A method of inhibiting a cancer cell growth includes contacting the cancer cell with a Cu2(OH)3NO3 / CaSiO3@g-C3N4 nanocomposite material containing graphitic carbon nitride (g-C3N4), copper hydroxide nitrate (Cu2(OH)3NO3) and calcium silicate (CaSiO3), achieving an inhibition efficiency on human breast carcinoma (MCF-7) and human hepatocellular carcinoma (HepG-2) cell growth of greater than 95% in an in-vitro cellular viability assay.

Disclosed are methods for detecting and treating cancers (such as carcinoma, leukemia, lung cancer, colon cancer, central nervous system (CNS) cancer, melanoma, ovarian cancer, renal cancer, oral cancer, prostate cancer and / or breast cancer). The method may include receiving a sample from a patient (such as a sample from a biopsy, a sample from an extracellular vesicle, or a sample from a circulating tumor cell). The method may include determining whether a LY6C protein or a phosphorylated ANXA2 protein is detected in the sample. The method may include treating a patient for cancer by targeting the LY6C protein when the LY6C protein is detected (e.g., using photoimmunotherapy (PIT) or near infrared photoimmunotherapy (NIR-PIT)). or treating a patient for cancer by targeting an ANXA2 protein (e.g, using inhibitors, decoys, etc.) when the phosphorylated ANXA2 protein is detected.

The present disclosure provides novel compounds, compositions, and methods for modulating one or more septin proteins, e.g., septin-2. Such compounds and compositions are useful for the treatment of a cancer, e.g., endometrial, pancreatic, lung, breast or ovarian cancer, such as serous and ovarian clear cell carcinoma.

Bryostatin-1 stimulates the expression of tumor associated antigens in hematologic and other tumors, enabling these tumors to be recognized by immunotherapies, and increasing clinical responses to various immunotherapies. Accordingly, a method of treating cancer in a subject by administration of bryostatin-1 or functional analogs based on this paradigm is provided herein.

Antibody drug conjugate (ADC) comprising a drug moiety conjugated to antibody or antigen binding fragments thereof that bind to TROP2 disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The ADC of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the ADC disclosed herein can include carcinomas, such as lung cancer, breast cancer, head-and-neck cancer, esophagus cancer, stomach cancer, bladder cancer, pancreatic cancer, colorectal cancer, cervix cancer, endometrial cancer, ovarian cancer, laryngeal cancer, prostate cancer, thyroid cancer and oral cancer.

A method of inhibiting cell growth in a cancer includes contacting a graphite-phase carbon nitride copper oxide and magnesium aluminum oxide (g-C3N4@CuO / MgAl2O4) nanocomposite with the cancer to inhibit growth of the cancer. The g-C3N4@CuO / MgAl2O4 nanocomposite comprises a graphite-phase carbon nitride (g-C3N4) in an amount of 2 to 18 percent by weight (wt. %), copper oxide in an amount of 1 to 10 wt. %, and magnesium aluminum oxide (MgAl2O4) in an amount of 75 to 95 wt. % based on a total weight of the g-C3N4@CuO / MgAl2O4 nanocomposite. The cancer includes cells from a cell line selected from a group consisting of a human hepatocellular carcinoma (HepG-2) cell line and a human breast carcinoma (MCF-7) cell line.

Several embodiments of the methods and compositions disclosed herein relate to immune cells engineered to express cytotoxic chimeric receptors and various dosing regimens for administering such cells. In several embodiments, the immune cell expresses a chimeric receptor that targets a ligand of NKG2D on a tumor cell. In several embodiments, the cancer is a leukemia, e.g., acute myelogenous leukemia (e.g., recurrent / refractory acute myelogenous leukemia) or myelodysplastic syndrome. In several embodiments, the tumor is a solid tumor, such as breast cancer, cervical cancer, colorectal cancer, gastric cancer, head and neck cancer, hepatocellular cancer, lung cancer, melanoma, intrahepatic cholangiocarcinoma, or other liver tumor, such as a secondary metastatic tumor from colorectal cancer. In several embodiments, the immune cells are administered in combination with a therapeutic agent, such as an additional anti-cancer agent.

The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and / or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.

The present invention discloses a red kidney bean defensin and its antibacterial and antitumor activity and application, and belongs to the field of molecular biology technology. The present invention identifies and obtains a brand-new defensin D1 from red kidney bean, and the nucleotide sequence is shown in SEQ ID NO.1. Defensin D1 can be used to inhibit Staphylococcus epidermidis, Bacillus subtilis, and Pseudomonas aeruginosa. Further, the results of tumor inhibition activity identification show that it has anti-human breast cancer cells, human ovarian adenocarcinoma cells, human lung cancer cells, and human glioma cells. Defensin D1 has an antibacterial effect and also has the function of inhibiting tumor activity, has a wide range of application prospects, and its potential is worth further exploration.

It has been previously demonstrated that the RAC2 G12R mutation rapidly induced cell death and hematopoietic control of HSPCs. Now, the present inventors have evaluated the effect of said mutation on three tumor cell lines: MDA-MB-231 (breast adenocarcinoma), HT29 (colon adenocarcinoma) and HepG2 (hepatocellular carcinoma). Briefly, cells were transduced with lentiviral vectors containing a green fluorescent protein (GFP) reporter cDNA (WPI) or a wild-type form of RAC2 cDNA (WT) or a RAC2 mutant cDNA form (G12R). The inventors showed that the number of GFP+ cells was dramatically reduced in the G12R condition compared to the WT and WPI conditions. The morphology and contents of the cells were particularly disrupted. These observations were confirmed in a time-course proliferation assay performed on MDA-MB-231 and HT29 cell lines. In summary, these data provide the basis for the deleterious effect of the RAC2 G12R mutation on the proliferation of tumor cell lines.

NEO-201 is a humanized IgG1 monoclonal antibody (mAb) that is highly reactive against the majority of tumor tissues from a number of different cancer tumors, including colon, pancreatic, gastric, lung, breast and uterine cancers, but the majority of normal tissues are not recognized by such antibodies. Functional assays reveal that NEO-201 is capable of mediating both antibody dependent cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) against tumor cells. Furthermore, the growth of human pancreatic xenograft tumors in vivo is greatly weakened by using NEO-201 alone and in combination with human peripheral blood mononuclear cells (PBMCs) that are effector cell sources for ADCC. In-vivo biological distribution research in mice carrying human tumor xenografts reveals that NEO-201 is preferentially accumulated in tumors rather than organ tissues. Single dose toxicity studies in non-human primates demonstrate the safety and tolerance of NEO-201 because the transient reduction of circulating neutrophils is the sole associated side effect observed.

The present technology provides compounds, as well as compositions including such compounds, useful for imaging and / or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and / or a prostate cancer.

The present invention relates to 1,2-dicarboxamide compounds of Formula (I); pharmaceutically acceptable salts, pharmaceutically acceptable stereoisomers, N-oxides or combination thereof, wherein 'X', 'Y', 'Z', ring A, ring B, R1, R2, R3, R4, R5, R6, 'm' and 'n' are as defined herein. The present invention also relates to 1,2-dicarboxamide compounds that modulate cellular activities like proliferation, differentiation, adhesion, migration and apoptosis by modulating protein kinase enzymatic activity. In particular the invention relates to compounds which inhibit, regulate, and / or modulate tyrosine kinases such as FLT1 (VEGFR1), FLT4 (VEGFR3), KDR (VEGFR2), MET (C-Met), MERTK (c-Mer), RET, AXL, TEK (TIE 2) and EGFR. The present disclosure relates to 1,2-dicarboxamide compounds for use in modulating kinase enzymatic activity and accordingly modulating kinase-dependent associated diseases and conditions such as cancers like Thyroid carcinoma, Ovarian carcinoma, Pancreatic carcinoma, Prostatic carcinoma, Renal cell carcinoma, Hepatocellular carcinoma, Breast carcinoma, Colorectal carcinoma, Oral squamous cell carcinoma, Colorectal, Lung adenocarcinoma or Endometrial cancer.

The invention provides a nitrogen-containing polycyclic aromatic compound as well as a preparation method and application thereof. The nitrogen-containing polycyclic aromatic compound has a structure as shown in a formula I and has excellent broad-spectrum anti-tumor activity. The compound especially shows a certain degree of inhibition rate on gastric cancer cells AGS, cervical cancer cells Hela, cervical cancer cells SiHa, lung cancer cells A549, liver cancer cells HuH-7, liver cancer cells Mahlavu, breast cancer cells MCF-7, triple negative breast cancer MDA-MA-231, colon cancer cells HCT116, esophageal squamous cell carcinoma TE-1, pancreatic ductal adenocarcinoma SUIT-2, multiple myeloma KMS-11, osteosarcoma U-2 OS, endometrial cancer HEC-151, colorectal cancer DLD-1 and the like. Therefore, the compound shown in the formula I can be used as a lead compound for research of novel broad-spectrum antitumor drugs.

The present invention relates to a compound of formula (I) wherein R1 represents a halogen atom, a (C1-C6) alkyl group, a (C3-C6) cycloalkyl group, a (C2-C6) alkenyl group, a (C1-C6) alkoxy group or a (C3-C6) cycloalkyloxy group, X and Y independently represent a-CH = group,-CR3 = group or-N = group, Z1 and Z2 independently represent a-CH2-group, an = CH-group or an = N-group, and R3 and R4 independently represent a hydrogen atom or a halogen atom, or any pharmaceutically acceptable salt thereof. The invention also relates to the use of the compounds as a medicament, in particular for the treatment and / or prevention of cancers, in particular cancers exhibiting recruitment of MDM2 to chromatin, the present invention relates to a cancer, more particularly a cancer selected from the group consisting of bone cancer, brain cancer, ovarian cancer, breast cancer, lung cancer, colorectal cancer, osteosarcoma, skin cancer, leukemia (including acute myelogenous leukemia), pancreatic cancer, prostate cancer and liposarcoma, even more particularly a cancer selected from the group consisting of skin cancer, liposarcoma and leukemia, such as but not limited to liposarcoma, melanoma and acute myelogenous leukemia.

Disclosed are methods for detecting and treating cancers (such as carcinoma, leukemia, lung cancer, colon cancer, central nervous system (CNS) cancer, melanoma, ovarian cancer, renal cancer, oral cancer, prostate cancer and / or breast cancer). The method may include receiving a sample from a patient (such as a sample from a biopsy, a sample from an extracellular vesicle, or a sample from a circulating tumor cell). The method may include determining whether a LY6C protein or a phosphorylated ANXA2 protein is detected in the sample. The method may include treating a patient for cancer by targeting the LY6C protein when the LY6C protein is detected (e.g., using photoimmunotherapy (PIT) or near infrared photoimmunotherapy (NIR-PIT)). or treating a patient for cancer by targeting an ANXA2 protein (e.g, using inhibitors, decoys, etc.) when the phosphorylated ANXA2 protein is detected.

The present invention relates to an alkyl diamine-substituted bis-aromatic heterocyclic thioether compound, a preparation thereof, and an application thereof in the preparation of drugs for treating and / or preventing tumors. The structural formula of the compound is as shown in formula (I): the compound has a clear growth-inhibitory effect on various human tumor cells, with good inhibitory activity against breast cancer, liver cancer, pancreatic cancer, kidney cancer, lung cancer, gastric cancer, glioma, ovarian cancer, prostate cancer, esophageal cancer, melanoma, nasopharyngeal carcinoma, colon cancer, cervical cancer, lymphoma, leukemia and other such tumors, wherein the effective IC50 concentration of the compound against tumor cells, such as breast cancer, pancreatic cancer, lung cancer, glioma, ovarian cancer, esophageal cancer, melanoma, colon cancer, cervical cancer, is lower than cisplatin, and experiments show that the compound has broad-spectrum anti-tumor activity. Experiments have further detected that the compound exhibits the effect of degrading PD-L1 proteins, and is a PD-L1 immunomodulator. The present invention provides a new approach for using alkyl diamine-substituted bis-aromatic heterocyclic thioether compounds in the preparation of drugs for treating and / or preventing tumors.

This invention relates to the preparation of 10-trifluoromethoxycamptothecin compounds and their use in antitumor drugs. The structural formula of these compounds is shown below. In vitro cytotoxicity screening results show that 10-trifluoromethoxycamptothecin compounds possess broad-spectrum antitumor activity, exhibiting strong inhibitory activity against human hepatocellular carcinoma cells (HepG2), human non-small cell lung cancer cells (A549), human colon cancer cells (SW480), human cholangiocarcinoma cells (QBC939), human breast cancer cells (MCF-7), human pancreatic cancer cells (PANC-1), and human pancreatic cancer cells (BxPC-3). Compounds 10-trifluoromethoxycamptothecin I and 7-ethyl-10-trifluoromethoxycamptothecin II showed strong inhibitory effects against all seven tested tumor cell lines, with IC50 values ​​exceeding 100%. 50 The concentrations were 0.913–0.0661 μM and 4.932–0.0578 μM, respectively, both significantly superior to the control drug topotecan. Among them, compounds I and II exhibited the strongest inhibitory activity against the BxPC-3 cell line, with IC50 values ​​of [missing value]. 50 The values ​​were 0.0661±0.0065μM and 0.0578±0.0043μM, respectively. Therefore, 10-trifluoromethoxycamptothecin compounds hold promise for development into a novel antitumor drug.

To provide a process for preparing MDM2 inhibitors useful for treating solid tumors such as breast, colon, lung, and prostate tumors, as well as liquid tumors such as lymphomas and leukemias.SOLUTION: Provided are commercial processes for preparing 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid and intermediates thereof.SELECTED DRAWING: Figure 1

Heterocyclic compounds, their stereoisomers and their pharmaceutically acceptable salts are useful in the treatment of many types of cancers, such as cancers of the breast, prostate, pancreatic, gastric, lung, colon, rectum, esophagus cancer, duodenum, tongue, pharynx, liver, kidney, bile duct, uterine body, cervix, ovaries, urinary bladder, and skin. Other cancers to be treated include brain tumor, neurinoma, clear cell carcinoma, non-small cell lung cancer, small cell lung cancer, hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer, bone tumor, vascular fibroma, glioblastoma, Neuroblastoma, sarcoma, neuroendocrine tumors, retinoblastoma, penile cancer, pediatric solid cancer, renal cell carcinoma, lymphoma, myeloma, leukemia, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, cutaneous T-cell lymphoma (CTCL), multiple myeloma (MM), myeloproliferative neoplasms (MPN), Myelodysplastic syndrome (MDS), polycythemia vera (PV), essential thrombocythemia, essential thrombocytosis (ET), and myelofibrosis (MF), and also including their metastases.

The invention discloses a VR device for assisting decision before breast tumor excision, and the device comprises a three-dimensional body scanner and a walking posture sensor, and is used for collecting the weight information of a breast tumor patient; after a tilting instruction is received, the patient tilts towards one side, so that the breast tumor patient feels tilting when watching the walking posture animation after the breast tumor is cut off; the VR helmet is used for outputting a walking posture animation before breast tumor excision and a walking posture animation after breast tumor excision to the breast tumor patient; different stimulation currents are output to the breast tumor patient, so that the breast tumor patient can feel pains in different periods after the breast tumor is cut off; and an upper computer. According to the auxiliary VR device, three-dimensional parameters of a patient before an operation can be obtained, animations of walking postures after mammary gland resection on one side are generated, and the animations are transmitted to the VR helmet, so that the patient can personally observe changes of the walking postures after the operation so as to assist the breast tumor patient to make corresponding decisions.

The present disclosure relates to using ivonescimab, an anti-VEGF x anti-PD-1 bispecific antibody, optionally in combination with other therapies, to treat cancers. Disclosed embodiments include: ivonescimab or ivonescimab in combination with ligufalimab to treat head and neck squamous cell carcinoma (e.g., PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma); perioperative ivonescimab or ivonescimab in combination with chemotherapy to treat resectable non-small cell lung cancer; ivonescimab in combination with chemotherapy or in combination with ligufalimab and chemotherapy to treat colorectal cancer (e.g., recurrent or metastatic colorectal cancer); ivonescimab to treat advanced non-small cell lung cancer; and ivonescimab in combination with chemotherapy to treat locally advanced unresectable or metastatic triple-negative breast cancer.